Effect of dose-optimized imatinib (IM) 800 mg on deep molecular responses (CMR 4.5) and prediction of survival: Results from the randomized CML-study IV.
Rüdiger Hehlmann
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Novartis
Michael Lauseker
No relevant relationships to disclose
Benjamin Hanfstein
Honoraria - Bristol-Myers Squibb
Martin C. Müller
No relevant relationships to disclose
Annette Schreiber
No relevant relationships to disclose
Ulrike Proetel
No relevant relationships to disclose
Markus Pfirrmann
No relevant relationships to disclose
Susanne Schnittger
Employment or Leadership Position - Celgene
Jolanta Dengler
No relevant relationships to disclose
Christiane Falge
No relevant relationships to disclose
Andreas Neubauer
No relevant relationships to disclose
Frank Stegelmann
No relevant relationships to disclose
Michael Pfreundschuh
No relevant relationships to disclose
Cornelius F. Waller
No relevant relationships to disclose
Karsten Spiekermann
No relevant relationships to disclose
Gabriela M. Baerlocher
No relevant relationships to disclose
Stefan W. Krause
Honoraria - Novartis
Research Funding - Novartis
Other Remuneration - Novartis
Andreas Hochhaus
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; MSD; Novartis; Pfizer
Joerg Hasford
Research Funding - Novartis
Susanne Saussele
No relevant relationships to disclose